Asfotase Alfa

Department of Health written question – answered on 19th October 2016.

Alert me about debates like this

Photo of John Glen John Glen Conservative, Salisbury

To ask the Secretary of State for Health, whether he plans to appeal NICE's draft guidance on asfotase alfa for treating paediatric-onset hypophosphatasia, issued in September 2016.

Photo of John Glen John Glen Conservative, Salisbury

To ask the Secretary of State for Health, what steps his Department is taking to ensure that asfotase alfa is available on the NHS to all patients who may benefit from it.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.

There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.

Does this answer the above question?

Yes2 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.